SCHEMBL5237497

SCHEMBL5237497

CCCCOc1c(CN2C(=O)c3ccccc3C2=O)n(CC(C)(C)C)c(=O)c2cc(F)ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
PTK2B Q14289 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CASP3 P42574 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
DPP4 P27487 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KMT2A Q03164 2/20 0.32
GRM5 P41594 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HSD17B10 Q99714 1/20 0.32
METAP2 P50579 1/20 0.32
MEN1 O00255 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
PARP1 P09874 1/20 0.32
BRD4 O60885 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5238249 0.96 TSHR (0.38) TSHRPTK2BNPC1RAB9ACASP3
SCHEMBL5233781 0.90 HPGD (0.39) TSHRPTK2BRAB9ADPP4MAPT
SCHEMBL5232925 0.89 TSHR (0.45) TSHRPTK2BRAB9ADPP4MAPT
SCHEMBL5236922 0.89 PTGDR2 (0.38) TSHRPTK2BPTGDR2DPP4METAP2
SCHEMBL5237827 0.87 TSHR (0.42) TSHRPTK2BRAB9ACASP3MAPT
SCHEMBL5239302 0.87 TSHR (0.39) TSHRPTK2BRAB9ACASP3DPP4
SCHEMBL5238745 0.86 RORA (0.40) TSHRPTK2BRAB9ADPP4MAPT
SCHEMBL5236732 0.86 KDM4E (0.42) TSHRPTK2BRAB9ACASP3MAPT
SCHEMBL5239124 0.85 TSHR (0.40) TSHRPTK2BNPC1RAB9ACASP3
SCHEMBL5230945 0.85 RORA (0.39) TSHRPTK2BPTGDR2DPP4METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed
WO-2002062764-A9 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 TSHR 2475/4885PTK2B 3599/4885NPC1 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.